Europe Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional partnerships. She examines Europe’s evolving pharmaceutical landscape, from patent expiries and pricing pressure to growing attention on brain health, and…
Europe ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by a shared purpose, long-term vision and a commitment to improving patients’ lives. As the US grows in relevance and investment…
Europe Eight years into its shift into rare diseases, Ferrer is moving into a new phase as its pipeline matures. CEO Mario Rovirosa reflects on the setbacks and lessons shaping that journey, as well as the growing pressures on Europe’s ability to sustain innovation and patient access. Throughout, Ferrer’s commitment to…
Europe Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions alongside its established interventional business, and how closer pharma partnerships, continuous innovation and a deeply rooted culture are shaping its…
Europe Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority development programmes. As the group prepares potential launches in narcolepsy, psoriasis and polycythaemia vera, a rare blood cancer, Gamze Yuceland explains how patient insight,…
Germany Gerald Unden, General Manager DACH at Shionogi, believes that healthcare leadership begins with giving the patients of tomorrow a voice in the decisions made today. In this interview, he explains why antimicrobial resistance requires a long-term model of innovation, how Germany can help shape sustainable access to reserve antibiotics, and…
Europe The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO’s next phase of growth. He sets out the rationale behind investments in microbial, mammalian and advanced-therapy manufacturing, explains why the US is becoming central to…
Germany The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but turning that research into companies, clinical programmes and ultimately medicines remains a persistent challenge. From its Berlin base, ProBioGen sits…
Germany The opportunity to continue growing the organisation, while driving performance and innovation, remains a strong source of motivation Sobi’s rapid growth in Germany and across DACH-NL is opening a new chapter for the rare disease specialist, as an expanding portfolio, new therapeutic areas and a growing organisation reshape the business.…
Germany Our manufacturing base may be local, but the customers we serve and the products we manufacture are truly global Building on decades of microbial manufacturing expertise, Richter BioLogics is scaling its specialised CDMO model through expanded capacity in Germany and a growing international business. Managing Director Dr Kai Pohlmeyer discusses…
Europe The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its growth by combining targeted business development with a lean, entrepreneurial organisation that remains closely connected to local healthcare systems. Luigi…
Global Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity is enormous, as is the potential impact for government coffers and patients. Can Europe maintain its position as the industry’s…
See our Cookie Privacy Policy Here
